Ads
related to: copd treatments- Medicare & Insurance
Medicare or Insurance May Cover
Your Inogen One System!
- Price Match Guarantee
Save Now, Buy Direct From Inogen
Try It Risk-Free For 30 Days.
- Medicare & Insurance
Search results
Verona's ensifentrine garners favorable reviews ahead of anticipated US launch for COPD
BioPharma-Reporter· 3 days agoThe asset has gained positive opinions in the US market after data presented during the American...
Expert: If You're a Senior, Watch Out for These 7 Common Mental Health Issues
Cheapism via AOL· 1 hour agoSocial isolation, treatment of chronic pain, boredom, lack of purpose, sleep disorders, and other...
Medical Breakthroughs: New procedure treating COPD
KRGV Rio Grande Valley· 17 hours agoChronic obstructive pulmonary disease, also known as COPD, is a condition that limits airflow in and out of the lungs, making it difficult to breathe.
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type...
Morningstar· 6 days agoFood and Drug Administration (FDA) has extended by three months the target action date of its priority review of the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab ...
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
Zacks via Yahoo Finance· 6 days agoPer the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication...
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
Reuters via Yahoo News· 6 days agoFrench drugmaker Sanofi and its U.S. partner have been counting on expanding the use of the drug as...
Small Business - Austin Daily Herald | Austin Daily Herald
Austin Daily Herald· 3 days agoCOPD, a chronic respiratory condition, can drastically impact quality of life, making everyday tasks like walking or climbing stairs a struggle. Oftentimes, patients know ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoThe European Commission is expected to announce a final decision on the Dupixent application in the coming months.
FDA delays decision on Dupixent in COPD; Summit makes a bold claim
BioPharma Dive via Yahoo Finance· 6 days agoRegeneron and Sanofi now expect an FDA verdict in September. Elsewhere, Summit claimed victory over...
Boehringer Ingelheim's COPD and asthma inhalers are now available for $35 a month for eligible...
KOLR - KSFX Ozarks· 5 days agoBoehringer Ingelheim's new program to cap out-of-pocket costs at $35 per month for eligible patientsi for the company's inhalers is now available. With this program, patients who have had difficulty ...